Dabigatran 110mg (Dabigatran Etexilate Mesilate Capsule) 110mg

Dabigatran etexilate mesilate works by directly inhibiting thrombin, a key enzyme in the blood clotting process. By inhibiting thrombin, it prevents the conversion of fibrinogen to fibrin, thereby reducing the formation of blood clots.

The usual dose of Dabigatran 110mg is determined by a healthcare professional based on the patient's condition, age, and other factors. It is typically taken as one 110mg capsule twice daily, but the prescriber sets the exact regimen.

The safety of Dabigatran 110mg during pregnancy or breastfeeding has not been established. It is generally recommended to avoid using this medication during pregnancy unless clearly necessary. Consult a healthcare professional for personalized advice.

To order Dabigatran 110mg from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then provide pricing, availability, shipping, and the necessary import paperwork.

Dabigatran 110mg is a direct thrombin inhibitor, while warfarin is an anticoagulant that works by inhibiting vitamin K-dependent clotting factors. Dabigatran offers the advantage of fixed dosing without the need for regular monitoring of blood clotting levels, unlike warfarin, which requires frequent blood tests.

Dabigatran 110mg should be stored at room temperature between 59°F to 86°F (15°C to 30°C). Keep the medicine in a dry place, protect the capsules from moisture, and keep them out of the reach of children. Once the bottle is opened, it should be used within 4 months.

Dabigatran 110mg is administered orally in the form of capsules. The capsules should be swallowed whole with a glass of water, and they can be taken with or without food. The exact dosing regimen is determined by a healthcare professional.

The most serious risks associated with Dabigatran 110mg include major gastrointestinal bleeding, unexplained falls in haemoglobin or haematocrit, and severe allergic reactions. Patients should be monitored closely for signs of bleeding and other adverse effects.

Dabigatran 110mg should not be used by patients with prosthetic heart valves, those with active pathological bleeding, and those with a history of severe hypersensitivity to dabigatran. It should also be used with caution in patients with an increased risk of bleeding or with concomitant use of certain medications.